Skip to main content

Taclonex FDA Approval History

FDA Approved: Yes (First approved January 9, 2006)
Brand name: Taclonex
Generic name: calcipotriene and betamethasone dipropionate
Dosage form: Ointment
Company: LEO Pharma
Treatment for: Psoriasis

Taclonex is a topical ointment containing a combination of calcipotriene and betamethasone for the treatment of psoriasis vulgaris in adults.

Development timeline for Taclonex

May 12, 2008Approval FDA Approves Taclonex Scalp - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
Jan 11, 2006Approval FDA Approves Taclonex - Once Daily Therapy for Treatment of Psoriasis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.